{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:44:46Z","timestamp":1775486686585,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,23]]},"DOI":"10.7759\/cureus.44003","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:52:11Z","timestamp":1692838331000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance"],"prefix":"10.7759","author":[{"given":"Atsuhiro","family":"Kitaura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushige","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tsukimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal DM","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, et al.. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015, 373:2413-24. 10.1056\/NEJMoa1510991","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.11.052","article-title":"Andexanet alfa induced heparin resistance: when anticoagulation really remains reversed","volume":"35","author":"Erdoes G","year":"2021","unstructured":"Erdoes G, Birschmann I, Nagler M, Koster A. Andexanet alfa induced heparin resistance: when anticoagulation really remains reversed. J Cardiothorac Vasc Anesth. 2021, 35:908-9. 10.1053\/j.jvca.2020.11.052","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.09.091","article-title":"Andexanet alfa use in cardiac surgical patients: A Xa inhibitor and heparin reversal agent","volume":"35","author":"Levy JH","year":"2021","unstructured":"Levy JH, Connors JM. Andexanet alfa use in cardiac surgical patients: A Xa inhibitor and heparin reversal agent. J Cardiothorac Vasc Anesth. 2021, 35:265-6. 10.1053\/j.jvca.2020.09.091","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu G","year":"2013","unstructured":"Lu G, DeGuzman FR, Hollenbach SJ, et al.. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013, 19:446-51. 10.1038\/nm.3102","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-018-1617-2","article-title":"Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy","volume":"45","author":"Sartori M","year":"2018","unstructured":"Sartori M, Cosmi B. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. J Thromb Thrombolysis. 2018, 45:345-52. 10.1007\/s11239-018-1617-2","journal-title":"J Thromb Thrombolysis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report","volume":"13","author":"Flaherty D","year":"2019","unstructured":"Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L. Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report. A A Pract. 2019, 13:271-3. 10.1213\/XAA.0000000000001052","journal-title":"A A Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful antithrombin administration in andexanet alfa associated heparin resistance","volume":"35","author":"Apostel HJ","year":"2021","unstructured":"Apostel HJ, Winckers K, Bidar E, Schreiber JU.  Successful antithrombin administration in andexanet alfa associated heparin resistance. J Cardiothorac Vasc Anesth. 2021, 35:904-7. 10.1053\/j.jvca.2020.10.042","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015368126304","article-title":"Argatroban","volume":"13","author":"Kathiresan S","year":"2002","unstructured":"Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis. 2002, 13:41-7. 10.1023\/a:1015368126304","journal-title":"J Thromb Thrombolysis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2009.215848","article-title":"Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?","volume":"10","author":"Follis F","year":"2010","unstructured":"Follis F, Filippone G, Montalbano G, Floriano M, Lobianco E, D'Ancona G, Follis M. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?. Interact Cardiovasc Thorac Surg. 2010, 10:592-6. 10.1510\/icvts.2009.215848","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00088.x","article-title":"Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane","volume":"7","author":"Nakae H","year":"2003","unstructured":"Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003, 7:483-5. 10.1046\/j.1526-0968.2003.00088.x","journal-title":"Ther Apher Dial"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.03.030","article-title":"Cardiopulmonary bypass strategy with low-dose heparin and nafamostat mesilate in cardiac surgery: a safe option for patients with acute stroke","volume":"144","author":"Morimoto N","year":"2012","unstructured":"Morimoto N, Henmi S, Yoshida M, Mukohara N. Cardiopulmonary bypass strategy with low-dose heparin and nafamostat mesilate in cardiac surgery: a safe option for patients with acute stroke. J Thorac Cardiovasc Surg. 2012, 144:726-8. 10.1016\/j.jtcvs.2012.03.030","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)01513-3","article-title":"Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass","volume":"77","author":"Kaminishi Y","year":"2004","unstructured":"Kaminishi Y, Hiramatsu Y, Watanabe Y, Yoshimura Y, Sakakibara Y. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg. 2004, 77:644-50. 10.1016\/S0003-4975(03)01513-3","journal-title":"Ann Thorac Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2011.09.002","article-title":"Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"26","author":"Kikura M","year":"2012","unstructured":"Kikura M, Tanaka K, Hiraiwa T, Tanaka K. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2012, 26:239-44. 10.1053\/j.jvca.2011.09.002","journal-title":"J Cardiothorac Vasc Anesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/180635-successful-nafamostat-mesilate-administration-for-andexanet-alfa-induced-heparin-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:40Z","timestamp":1707508360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/180635-successful-nafamostat-mesilate-administration-for-andexanet-alfa-induced-heparin-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.44003","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}